KRCA-0008
CAS No. : 1472795-20-2
| Size | Price | Stock |
|---|---|---|
| 5mg | $50 | In-stock |
| 10mg | $70 | In-stock |
| 25mg | $140 | In-stock |
| 50mg | $240 | In-stock |
| 100mg | $400 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-12331 |
| M.Wt: | 609.12 |
| Formula: | C30H37ClN8O4 |
| Purity: | >98 % |
| Solubility: | DMSO : 230 mg/mL (ultrasonic) |
KRCA-0008 is a selective ALK/Ack1 inhibitor with IC50s of 12 and 4 nM for ALK and Ack1, respectively. KRCA-0008 can be used for the research of cancer[1][2]. IC50 & Target:IC50: 12 nM (ALK), 4 nM (Ack1)[1] In Vitro:KRCA-0008 (0-1000 μM) shows potency to ALK (wt), ALK L1196 M, ALK C1156Y, ALK F1174L, ALK R1275Q and insulin receptor with IC50s of 12, 75, 4, 17, 17 and 210 nM, respectively[1]. KRCA-0008 (0-1000 nM; 4 h) inhibits ALK-dependent signaling pathways more potently than crizotinib[2]. KRCA-0008 (0-1000 nM; 72 h) induces cell apoptosis[2]. KRCA-0008 (0-100 nM; 48 h) affects cell cycle[2]. In Vivo:KRCA-0008 (25 and 50 mg/kg; p.o. twice a day for two weeks) suppresses tumor growth in an ALK-positive Karpas-299 xenograft model[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- KRCA-0008
- Cat. No.:
- HY-12331
- Quantity:
Your information is safe with us.